整合医疗系统中实施苯二氮䓬类药物节制戒酒医嘱套件后的结局
本研究为在Kaiser Permanente北加州整合医疗系统开展的差中差质量改进研究,纳入2014年10月1日至2019年9月30日共22 899例成人酒精戒断综合征(AWS)住院。2018年10月1日实施包含加巴喷丁、丙戊酸、可乐定和右美托咪定等辅助治疗的苯二氮䓬类药物节制AWS医嘱套件。在医嘱套件使用住院中,任何苯二氮䓬类药物使用从实施前6431例(78.1%)降至实施后2823例(60.7%)(P < .001),劳拉西泮平均总剂量从19.7 mg降至6.0 mg(P < .001)。与未使用医嘱套件的AWS住院相比,使用该医嘱套件与ICU使用率(ARR 0.71;95% CI 0.56-0.89;P = .003)和住院时间(ARR 0.71;95% CI 0.58-0.86;P < .001)降低相关。
要点
- 在医嘱套件使用住院中,任何苯二氮䓬类药物使用从实施前6431例住院(78.1%)降至实施后2823例住院(60.7%)(P < .001)。
- 劳拉西泮平均(SD)总剂量从实施前19.7(38.3)mg降至实施后6.0(9.1)mg(P < .001)。
- 与未使用医嘱套件的AWS住院相比,使用苯二氮䓬类药物节制医嘱套件与ICU使用率降低相关(ARR 0.71;95% CI 0.56-0.89;P = .003)。
- 与未使用医嘱套件的AWS住院相比,使用苯二氮䓬类药物节制医嘱套件与住院时间降低相关(ARR 0.71;95% CI 0.58-0.86;P < .001)。
- 辅助用药使用从实施前至实施后显著变化:加巴喷丁2413例住院(29.3%)vs 2814例住院(60.5%)(P < .001);可乐定1476例住院(17.9%)vs 2208例住院(47.5%)(P < .001);硫胺素6298例住院(76.5%)vs 4047例住院(87.0%)(P < .001);丙戊酸109例住院(1.3%)vs 256例住院(5.5%)(P < .001);
适用人群与场景
- 2014年10月1日至2019年9月30日Kaiser Permanente北加州整合医疗服务系统内22 899例成人酒精戒断综合征住院,来自16 323例 unique 患者(平均[SD]年龄57.1[14.8]岁;15 764例[68.8%]男性)。
处置流程与药物剂量
- 2018年10月1日实施苯二氮䓬类药物节制AWS住院医嘱套件,包含辅助治疗(如加巴喷丁、丙戊酸、可乐定和右美托咪定)。
研究设计与关键结果
- 研究类型为差中差质量改进研究,纳入22 899例AWS成人住院,来自Kaiser Permanente北加州整合医疗服务系统;研究期间该系统共904 540例住院,AWS占22 899例住院(2.5%)。
- 22 899例AWS住院中12 889例(56.3%)使用了戒酒医嘱套件。
- 在医嘱套件使用住院中,任何苯二氮䓬类药物使用从实施前6431例住院(78.1%)降至实施后2823例住院(60.7%)(P < .001);劳拉西泮平均(SD)总剂量从实施前19.7(38.3)mg降至实施后6.0(9.1)mg(P < .001)。
- 辅助用药从实施前至实施后变化:加巴喷丁2413例住院(29.3%)vs 2814例住院(60.5%)(P < .001);可乐定1476例住院(17.9%)vs 2208例住院(47.5%)(P < .001);硫胺素6298例住院(76.5%)vs 4047例住院(87.0%)(P < .001);丙戊酸109例住院(1.3%)vs 256例住院(5.5%)(P < .001);苯巴比妥412例住院(5.0%)vs 292例住院(6.3%)(P = .003)。
- 与未使用医嘱套件的AWS住院相比,使用苯二氮䓬类药物节制医嘱套件与ICU使用率降低相关(ARR 0.71;95% CI 0.56-0.89;P = .003),与住院时间降低相关(ARR 0.71;95% CI 0.58-0.86;P < .001)。
证据类型、等级与局限
- 证据类型:差中差质量改进研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,实施苯二氮䓬类药物节制AWS医嘱套件与苯二氮䓬类药物使用减少及结局有利趋势相关。
- 作者认为,这些发现提示需要进一步前瞻性研究以确定酒精戒断住院患者最有效的治疗方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Alcohol withdrawal syndrome (AWS) is a common inpatient diagnosis managed primarily with benzodiazepines. Concerns about the adverse effects associated with benzodiazepines have spurred interest in using benzodiazepine-sparing treatments.
OBJECTIVE: To evaluate changes in outcomes after implementation of a benzodiazepine-sparing AWS inpatient order set that included adjunctive therapies (eg, gabapentin, valproic acid, clonidine, and dexmedetomidine).
DESIGN, SETTING, AND PARTICIPANTS: This difference-in-differences quality improvement study was conducted among 22 899 AWS adult hospitalizations from October 1, 2014, to September 30, 2019, in the Kaiser Permanente Northern California integrated health care delivery system. Data were analyzed from September 2020 through November 2021.
EXPOSURES: Implementation of the benzodiazepine-sparing AWS order set on October 1, 2018.
MAIN OUTCOMES AND MEASURES: Adjusted rate ratios for medication use, inpatient mortality, length of stay, intensive care unit admission, and nonelective readmission within 30 days were calculated comparing postimplementation and preimplementation periods among hospitals with and without order set use.
RESULTS: Among 904 540 hospitalizations in the integrated health care delivery system during the study period, AWS was present in 22 899 hospitalizations (2.5%), occurring among 16 323 unique patients (mean [SD] age, 57.1 [14.8] years; 15 764 [68.8%] men). Of these hospitalizations, 12 889 (56.3%) used an order set for alcohol withdrawal. Among hospitalizations with order set use, any benzodiazepine use decreased after implementation from 6431 hospitalizations (78.1%) to 2823 hospitalizations (60.7%) (P < .001), with concomitant decreases in the mean (SD) total dosage of lorazepam before vs after implementation (19.7 [38.3] mg vs 6.0 [9.1] mg; P < .001). There were also significant changes from before to after implementation in the use of adjunctive medications, including gabapentin (2413 hospitalizations [29.3%] vs 2814 hospitalizations [60.5%]; P < .001), clonidine (1476 hospitalizations [17.9%] vs 2208 hospitalizations [47.5%]; P < .001), thiamine (6298 hospitalizations [76.5%] vs 4047 hospitalizations [87.0%]; P < .001), valproic acid (109 hospitalizations [1.3%] vs 256 hospitalizations [5.5%]; P < .001), and phenobarbital (412 hospitalizations [5.0%] vs 292 hospitalizations [6.3%]; P = .003). Compared with AWS hospitalizations without order set use, use of the benzodiazepine-sparing order set was associated with decreases in intensive care unit use (adjusted rate ratio [ARR], 0.71; 95% CI, 0.56-0.89; P = .003) and hospital length of stay (ARR, 0.71; 95% CI, 0.58-0.86; P < .001).
CONCLUSIONS AND RELEVANCE: This study found that implementation of a benzodiazepine-sparing AWS order set was associated with decreased use of benzodiazepines and favorable trends in outcomes. These findings suggest that further prospective research is needed to identify the most effective treatments regimens for patients hospitalized with alcohol withdrawal.
参考来源
- Smith JT, Sage M, Szeto H, et al. Outcomes After Implementation of a Benzodiazepine-Sparing Alcohol Withdrawal Order Set in an Integrated Health Care System. JAMA Netw Open. 2022. PMID: 35191968. doi:10.1001/jamanetworkopen.2022.0158
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。